One merchant, multiple MIDs
A single peptide brand can — and in 2026 should — hold multiple MIDs at different acquiring banks. This is called a "dual-backend" or "multi-MID" architecture. If one MID is suspended (often without warning), volume routes automatically to the backup MID with zero downtime.
What can terminate a MID
- Excessive chargebacks (above Mastercard's published thresholds — see chargeback-ratio glossary)
- BRAM violations (selling outside your declared MCC, missing LegitScript certification, FDA warning letter without remediation)
- Sudden volume changes (3–5× spikes flag automated risk review)
- Compliance review failures (LegitScript revocation, NACHA audit findings, etc.)
Why pre-underwriting a backup MID matters
When a MID terminates, applying for a new account can start from zero and may create downtime. The practical lesson for peptide merchants is to choose a program with clear underwriting, strong compliance review, and payout options planned before trouble starts.
How PeptideApprove issues MIDs
PeptideApprove focuses on getting compliant merchants through a clearer sponsor-bank review process with fixed 5% all-in pricing for approved card processing merchants. If additional payment pathways are appropriate, they are handled through written program terms.